0OT.SG - Ocular Therapeutix Inc

Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -14.81% and 4.62%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

• 
  Can nVent (NVT) Run Higher on Rising Earnings Estimates?

  Zacks
• 
  Can Abercrombie (ANF) Run Higher on Rising Earnings Estimates?

  Zacks

Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Intrinsic Value Is Potentially 32% Above Its Share Price

Key Insights Ocular Therapeutix's estimated fair value is US$8.20 based on 2 Stage Free Cash Flow to Equity Ocular...

Ocular Therapeutix (NASDAQ:OCUL) shareholders have endured a 21% loss from investing in the stock five years ago

It is a pleasure to report that the Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) is up 40% in the last quarter. But over...

What Makes Ocular Therapeutix (OCUL) a Good Fit for 'Trend Investing'

Ocular Therapeutix (OCUL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Ocular Therapeutix Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

Ocular Therapeutix ( NASDAQ:OCUL ) Full Year 2022 Results Key Financial Results Revenue: US$51.5m (up 18% from FY...

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 4% and 3.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Chinook Therapeutics (KDNY) Reports Q4 Loss, Tops Revenue Estimates

Chinook (KDNY) delivered earnings and revenue surprises of -13.92% and 28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Shares of Ocular Therapeutix Jumped This Week

Shares of Ocular Therapeutix (NASDAQ: OCUL) were up by 49.6% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The biopharmaceutical company specializes in finding therapies to treat diseases and conditions of the eye. The healthcare company, on Feb. 11, announced preliminary 10-month data on its phase 1 trial of OTX-TKI, an axitinib (a small molecule, multitarget, tyrosine kinase inhibitor) intravitreal (inside the eye) hydrogel implant to treat age-related macular degeneration (AMD), diabetic retinopathy and other diseases of the retina.

With 48% stake, Ocular Therapeutix, Inc. (NASDAQ:OCUL) seems to have captured institutional investors' interest

Every investor in Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) should be aware of the most powerful shareholder groups. We...

These Analysts Just Made A Neat Downgrade To Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Forecasts

Market forces rained on the parade of Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) shareholders today, when the analysts...

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised)

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -30.43% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -34.78% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Investors in Ocular Therapeutix (NASDAQ:OCUL) have unfortunately lost 63% over the last year

Investing in stocks comes with the risk that the share price will fall. Unfortunately, shareholders of Ocular...

Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock?

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Ocular Therapeutix (OCUL) Reports Q2 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -21.74% and 11.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Could The Ocular Therapeutix, Inc. (NASDAQ:OCUL) Ownership Structure Tell Us Something Useful?

If you want to know who really controls Ocular Therapeutix, Inc. ( NASDAQ:OCUL ), then you'll have to look at the...

Is Ocular Therapeutix (NASDAQ:OCUL) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...